Roflumilast is not intended to treat another form of COPD which involves primary emphysema.
罗氟司特不被期望用于COPD其它症状，包括肺气肿的治疗。
2
Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor, which has potent anti-inflammatory effects in the pulmonary system.
罗氟司特为磷酸二酯酶- 4 (PDE4)抑制剂，对肺部系统具有高效的抗炎活性。
3
The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast.